This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Low molecular weight heparin & thromboprophylaxis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

In patients undergoing surgery on hips or knees the risk of deep venous thrombosis (DVT) is 50-70%. In patients not receiving thromboprophylaxis 0.1-0.4% will die from pulmonary embolism.

Anticoagulant thromboprophylaxis treatments include:

  • low-dose unfractionated heparin
  • low-molecular-weight heparin
  • warfarin
  • recombinant hirudin

Despite these treatments 16-30% of hip replacement patients will develop venographically proven DVTs.

The thromboprophylactic dose of low molecular weight heparin is 5000 U twice a day.LMWH reduced the risk of DVT in patients post-total hip replacement by 31-79%. LMWH was as effective as full dose heparin but had a lower incidence of bleeding.

LMWH is also a safe and effective in prevention of DVT in patients undergoing total knee replacement.

Data suggests that a synthetic heparin analogue (fondaparinux) may be superior to LMWH.

Reference:

  • Weitz, JI (1997). Low-molecular-weight heparins. NEJM, 337, 689-698.
  • The Columbus Investigators (1997). Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. NEJM, 337, 657-62.

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.